IMNM Company Profile and Key Details

IMNM has shown sold momentum, gaining 16.09% over the past week and 52.39% over the past quarter, though year-to-date performance is up 11.17%. Short-term trend indicators are bearishly aligned (SMA20 -7.21%, SMA50 -3.65%, SMA200 49.17%). The stock’s 14-day RSI is 43.63 (neutral), while the ATR of 1.33 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -20.83% below its high and over 325.04% above its low. Average 10-day trading volume of 1.35 million shares is in line with the 3-month average of 1.28 million, indicating normal recent market interest.

Immunome, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $7.27. This means the shares are trading above this model’s fair value.

Immunome, Inc. has 87.05 million shares outstanding. The public float is 70.81 million shares, elevated short interest at 17.06% of float. This equals 14.21 million shares. The short ratio is 12.83 days. Institutional investors hold 115.11% of the float. Insiders own 6.3%. SIEGALL CLAY B holds 690.70 thousand shares, WAGENHEIM PHILIP has 341.15 thousand shares and RAPP MICHAEL has 208.74 thousand shares. Over the past six months, insider transactions show net selling. They sold 589.32 thousand shares across 19 transactions.

Immunome, Inc. generated EPS of -$2.96 over the past year. Five-year average earnings growth is -38.15%. Wall Street analysts project EPS growth of 24.09% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $40.00 to $26.00. The high target offers 66.88% upside. The low target suggests 8.47% downside. The mean target is $34.71. This offers 44.81% upside. Immunome, Inc. earnings surprise history is a mixed track record. The quarter that ended August 11, 2026, missed forecasts by 26.51%. The prior quarter beat by -20.0%. Over the last six quarters, Apple has recorded several small beats. These include -21.21% in May 12, 2025.

Immunome, Inc. (NASDAQ:IMNM) closed at $23.97 USD, gaining $0.04 (0.17%) from the previous close of $23.93. The stock is currently mid-range between its 52-week high and low $9.36 and $30.06. With a market capitalization of about $2.29 billion, Immunome, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.13). Key stats such as the average daily volume over the past year has been around 1.30 million shares, trading with heavier-than-usual volume. Headquartered in Bothell, WA, Immunome, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Clay Siegall, the company employs approximately 247 people and listed since October 02, 2020. Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.

Immunome, Inc. trades at a P/E ratio of -9.44, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.17 trading at moderately above to book value. The P/FCF stands at -10.46, also below market averages.

Our AI price prediction model suggests that Immunome, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.27%, with price expected at $20.55 by October 02, 2026, within a range of $19.73 to $21.44 3-Month Outlook: Projected rise of 142.68%, reaching $58.17 by December 17, 2026, with a range of $57.30 to $59.30. 1-Year Outlook: Projected gain of 6.17%, with price at $25.45 by September 17, 2027, within a range of $23.46 to $27.41.

Immunome, Inc. (NASDAQ:IMNM) shares are up 11.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Immunome, Inc. trading at a premium to the broader market with a P/E of -9.44. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $29.26, suggesting 22.07% upside. Our AI forecast model points to short-term weakness (-14.27% over two weeks), a medium-term rise (142.68% over three months), and a longer-term gain (6.17% over one year), with expected trading ranges indicating moderate volatility.